{
    "clinical_study": {
        "@rank": "6617", 
        "acronym": "CORE-HIV", 
        "arm_group": [
            {
                "arm_group_label": "Recombinant Hepatitis B Virus Vaccine (High Dose)", 
                "arm_group_type": "Experimental", 
                "description": "Patients allocated to this arm will receive three doses of 40mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months."
            }, 
            {
                "arm_group_label": "Recombinant Hepatitis B Virus Vaccine (Standard Dose)", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients allocated to this arm will receive three doses of 20mcg each of recombinant hepatitis B vaccine (Engerix-B (R)). Doses will be administered at 0, 1 and 2 months."
            }
        ], 
        "brief_summary": {
            "textblock": "Hepatitis B virus infection is a common occurrence among patients with HIV. Effective\n      vaccines are available, but there's some uncertainty regarding specific dosages, specially\n      among those who have not responded to an initial vaccination. The purpose of this study is\n      to determine the effectiveness of a simplified immunization schedule compared to a high-dose\n      one."
        }, 
        "brief_title": "Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .", 
        "condition": [
            "Hepatitis B", 
            "HIV"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Virus Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Older than 18 years of age.\n\n          -  Patients infected with Human Immunodeficiency Virus (HIV)\n\n          -  Failed previous vaccination with a standard dose scheme of recombinant hepatitis B\n             vaccine (20mcg at 0, 1 and 6 months). Nonresponders will be considered as those\n             patients presenting a hepatitis B surface antigen antibody titer lower than 10UI/mL 4\n             to 8 weeks after the last dose of the vaccine.\n\n          -  Provision of informed consent.\n\n        Exclusion Criteria:\n\n          -  Proven Hepatitis B  virus infection (acute or chronic).\n\n          -  Proven hypersensitivity to the vaccine or any of its components."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02003703", 
            "org_study_id": "45/2012"
        }, 
        "intervention": {
            "arm_group_label": [
                "Recombinant Hepatitis B Virus Vaccine (High Dose)", 
                "Recombinant Hepatitis B Virus Vaccine (Standard Dose)"
            ], 
            "intervention_name": "Recombinant Hepatitis B Virus Vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Engerix B (GlaxoSmithKline)"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Vaccine", 
            "Primary Prevention", 
            "Immunogenicity"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "contact": {
                "email": "jivargasd@icloud.com", 
                "last_name": "Jose I Vargas, MD", 
                "phone": "62473415", 
                "phone_ext": "+56 9"
            }, 
            "contact_backup": {
                "email": "daniela_jensen@hotmail.com", 
                "last_name": "Daniela Jensen, MD", 
                "phone": "62473409", 
                "phone_ext": "+56 9"
            }, 
            "facility": {
                "address": {
                    "city": "Vi\u00f1a del Mar", 
                    "country": "Chile", 
                    "state": "Valpara\u00edso"
                }, 
                "name": "Hospital Gustavo Fricke"
            }, 
            "investigator": [
                {
                    "last_name": "Jose I Vargas, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Daniela Jensen, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Francisco Fuster, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Valeska Sarmiento", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Chile"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV : A Randomised Trial", 
        "overall_contact": {
            "email": "jivargasd@icloud.com", 
            "last_name": "Jose I Vargas, MD", 
            "phone": "62473415", 
            "phone_ext": "+56 9"
        }, 
        "overall_contact_backup": {
            "email": "daniela_jensen@hotmail.com", 
            "last_name": "Daniela Jensen, MD", 
            "phone": "62473409", 
            "phone_ext": "+56 9"
        }, 
        "overall_official": [
            {
                "affiliation": "Hospital Gustavo Fricke, Vi\u00f1a del Mar, Chile", 
                "last_name": "Francisco Fuster, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Escuela de Medicina, Universidad de Valpara\u00edso, Chile", 
                "last_name": "Jose I Vargas, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Escuela de Medicina, Universidad de Valpara\u00edso", 
                "last_name": "Daniela Jensen, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Centro de Investigaciones Biom\u00e9dicas, Escuela de Medicina, Universidad de Valpara\u00edso", 
                "last_name": "Felipe T Martinez, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Chile: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of participants with positive hepatitis B surface antigen (HBsAg) antibodies 4 to 8 weeks after completion of the vaccination schemes.", 
            "measure": "Serologic Response", 
            "safety_issue": "No", 
            "time_frame": "4-8 weeks After Exposure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02003703"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universidad de Valparaiso", 
            "investigator_full_name": "Felipe Martinez", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants presenting dermatologic reactions to the vaccine up to one week after exposure.", 
                "measure": "Local Reactions to Vaccine", 
                "safety_issue": "Yes", 
                "time_frame": "One Week after Exposure"
            }, 
            {
                "description": "Number of participants presenting any systemic adverse reaction attributable to vaccination.", 
                "measure": "Systemic Reactions to the Vaccine", 
                "safety_issue": "Yes", 
                "time_frame": "One Week after Exposure"
            }
        ], 
        "source": "Universidad de Valparaiso", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Roche Pharma AG", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "GlaxoSmithKline", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Aclin Laboratories, Chile", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Universidad de Valparaiso", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}